Nan Fung Trinity HK Ltd. Invests $2.04 Million in Kura Oncology, Inc. $KURA

Nan Fung Trinity HK Ltd. acquired a new stake in Kura Oncology, Inc. (NASDAQ:KURA) during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm acquired 230,880 shares of the company’s stock, valued at approximately $2,043,000. Nan Fung Trinity HK Ltd. owned approximately 0.27% of Kura Oncology as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of the business. EcoR1 Capital LLC boosted its stake in shares of Kura Oncology by 59.1% in the 2nd quarter. EcoR1 Capital LLC now owns 4,200,000 shares of the company’s stock valued at $24,234,000 after purchasing an additional 1,559,702 shares in the last quarter. Geode Capital Management LLC grew its position in Kura Oncology by 11.7% during the 2nd quarter. Geode Capital Management LLC now owns 2,014,029 shares of the company’s stock worth $11,623,000 after acquiring an additional 211,470 shares during the last quarter. Qube Research & Technologies Ltd increased its holdings in Kura Oncology by 63.0% in the 2nd quarter. Qube Research & Technologies Ltd now owns 1,911,886 shares of the company’s stock worth $11,032,000 after purchasing an additional 738,761 shares in the last quarter. Assenagon Asset Management S.A. raised its position in Kura Oncology by 37.6% in the third quarter. Assenagon Asset Management S.A. now owns 1,265,030 shares of the company’s stock valued at $11,196,000 after purchasing an additional 345,951 shares during the last quarter. Finally, AQR Capital Management LLC boosted its stake in shares of Kura Oncology by 23.9% during the second quarter. AQR Capital Management LLC now owns 941,675 shares of the company’s stock valued at $5,433,000 after purchasing an additional 181,343 shares in the last quarter.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on KURA shares. Wedbush reaffirmed an “outperform” rating and issued a $38.00 price objective (up previously from $36.00) on shares of Kura Oncology in a research note on Friday, November 14th. Leerink Partners set a $20.00 price target on shares of Kura Oncology and gave the stock an “outperform” rating in a report on Tuesday, January 13th. Citigroup restated a “market outperform” rating on shares of Kura Oncology in a report on Friday, December 5th. Zacks Research downgraded Kura Oncology from a “hold” rating to a “strong sell” rating in a report on Tuesday, January 20th. Finally, HC Wainwright reissued a “buy” rating and issued a $40.00 price target on shares of Kura Oncology in a research note on Tuesday, January 13th. Nine analysts have rated the stock with a Buy rating, two have assigned a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Kura Oncology has an average rating of “Moderate Buy” and a consensus price target of $28.00.

Insiders Place Their Bets

In other news, insider Teresa Brophy Bair sold 11,208 shares of the stock in a transaction dated Tuesday, January 27th. The shares were sold at an average price of $8.46, for a total transaction of $94,819.68. Following the transaction, the insider owned 226,931 shares of the company’s stock, valued at $1,919,836.26. This represents a 4.71% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Mollie Leoni sold 8,180 shares of the business’s stock in a transaction dated Tuesday, January 27th. The shares were sold at an average price of $8.46, for a total value of $69,202.80. Following the completion of the sale, the insider directly owned 267,274 shares of the company’s stock, valued at $2,261,138.04. The trade was a 2.97% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 104,411 shares of company stock valued at $1,035,994. 6.40% of the stock is currently owned by corporate insiders.

Kura Oncology Trading Down 1.2%

NASDAQ KURA opened at $8.12 on Friday. The stock has a market capitalization of $706.60 million, a P/E ratio of -3.27 and a beta of 0.25. The business has a 50 day simple moving average of $10.15 and a 200 day simple moving average of $9.05. The company has a debt-to-equity ratio of 0.02, a current ratio of 5.12 and a quick ratio of 5.12. Kura Oncology, Inc. has a one year low of $5.41 and a one year high of $12.49.

Kura Oncology (NASDAQ:KURA) last posted its quarterly earnings results on Tuesday, November 4th. The company reported ($0.85) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.28). The business had revenue of $20.75 million for the quarter, compared to the consensus estimate of $17.48 million. Kura Oncology had a negative return on equity of 65.42% and a negative net margin of 208.48%. Research analysts expect that Kura Oncology, Inc. will post -2.44 earnings per share for the current year.

Kura Oncology Profile

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.